Gemcitabine combined with cisplatin as adjuvant chemotherapy for non‐small cell lung cancer: A retrospective analysis

BACKGROUND: This study was conducted to evaluate the value of gemcitabine combined with cisplatin as adjuvant chemotherapy for radical resection of non‐small cell lung cancer. METHODS: Data of 100 patients who had undergone radical resection of non‐small cell lung cancer and were treated with cisplatin/gemcitabine as adjuvant chemotherapy between June 2007 and December 2010 at the Chinese Academy of Medical Sciences were reviewed. RESULTS: The median age was 59 years (range 36–73); 82% of the patients were male. Forty‐two percent had adenocarcinoma and 55% had squamous cell carcinoma. Most patients had pathologic IIB (29%) and IIIA (44%) stage disease. Eighty‐five percent of patients completed four cycles of chemotherapy, with 76% completing the planned full dose. The main reason for a reduced gemcitabine dose in 13 patients was grade 3/4 neutropenia or thrombocytopenia. The median dose and dose intensity were 8377.1 mg/m(2) and 708 mg/(m(2)/week) for gemcitabine and 293.38 mg/m(2) and 25.24 mg/(m(2)/week) for cisplatin, respectively. During follow‐up the median disease‐free survival was 33.8 months (95% confidence interval [CI] 15.938–51.676). Patients with squamous cell carcinoma (hazard ratio [HR] 0.404, 95% CI 0.241–0.676; P = 0.001) and pathologic stage I (HR 4.379, 95% CI 1.721–11.142; P = 0.002) achieved better disease‐free survival. The survival rates at one, two, and five years were 94%, 77%, and 55%, while the survival rates without recurrence were 64%, 53%, and 39%, respectively. CONCLUSION: As an adjuvant chemotherapy regimen, gemcitabine with cisplatin is well tolerated. Patients with squamous cell carcinomas or pathologic stage I achieve better results.